By Colin Kellaher

 

Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Tuesday said the European Commission approved the company's Byannli six-month maintenance treatment for schizophrenia in adults.

The drugmaker said the approval, which covers patients who are clinically stable on monthly or three-month doses, makes Byannli the first twice-yearly treatment of schizophrenia in adults in Europe.

The U.S. Food and Drug Administration in September approved a six-month version of the antipsychotic, marketed in the U.S. as Invega.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

November 23, 2021 07:03 ET (12:03 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Johnson and Johnson Charts.